Literature DB >> 15291866

Modified S-pouch neobladder vs ileal conduit and a matched control population: a quality-of-life survey.

Vassilis Protogerou1, Maria Moschou, Nikos Antoniou, John Varkarakis, Aris Bamias, Charalambos Deliveliotis.   

Abstract

OBJECTIVES: To measure the quality-of-life (QoL) outcome and urinary and sexual function and bother after radical cystectomy and different types of urinary tract reconstruction (Bricker vs modified S-pouch neobladder), also assessing differences between them and a normal population. PATIENTS, SUBJECTS AND METHODS: Two groups of patients with bladder cancer were assessed; group 1 comprised 58 (mean age 65 years, mean follow-up 28 months) with an ileal conduit diversion, and group 2, 50 (mean age 61 years, mean follow-up 26 months) with a modified S-pouch neobladder. All were disease-free. Group 3 comprised 54 healthy subjects (a control population) of similar age, gender and comorbidities other than bladder cancer. A QoL questionnaire was used to study changes in QoL, and a specific questionnaire for urinary and sexual function and bother was also constructed.
RESULTS: There were no differences in the QoL scores among the three groups; group 3 (control) tended to have a better QoL for all domains except emotional functioning. Urinary function was seriously affected in group 1, with more daytime leakage than in groups 2 and 3 (37.8% vs 10%, P = 0.005, and 9.3%, P = 0.01), night loss of urine (39.5% vs 28%, P = 0.07, and 3.7%, P = 0.002) and urine odour (58.6% vs 4%, and 5.5%, both P = 0.001). Patients in group 2 differed from healthy individuals only in night loss of urine. Consequently urinary bother was more pronounced in group 1, as fewer were satisfied (68.9% vs 86% and 83.2%, both P = 0.03). Sexual function was seriously and similarly affected in groups 1 and 2; the erection rate was 28.9% for group 1, 35.5% for group 2 (P = 0.1) and 83.3% in group 3 (P = 0.003), while firm erections were present at 17.7%, 22.2% (P = 0.2) and 83.3% (P = 0.002). Women reported equivalent dysfunction in all three groups (15.4%, 20% and 16.6%, P = 0.3). Sexual desire was also equal in all groups (48.2%, 50% and 48.1). Patients in group 1 expressed more bother, while those in group 2 seemed more satisfied by their sexual life (84.4%, 68% and 68.5%, P = 0.04).
CONCLUSIONS: Radical cystectomy does not affect QoL whichever urinary reconstruction is used, and this implies a determination by the patients to live and adjust to their new conditions. On the contrary, urinary and sexual function are affected and related to the method used to reconstruct the urinary system.

Entities:  

Mesh:

Year:  2004        PMID: 15291866     DOI: 10.1111/j.1464-410X.2004.04932.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  16 in total

Review 1.  [Quality of life after radical urologic pelvic surgery and impact of inpatient rehabilitation].

Authors:  O Dombo; U Otto
Journal:  Urologe A       Date:  2005-01       Impact factor: 0.639

2.  Determining when to recommend continent urinary diversion.

Authors:  Scott M Gilbert; James E Montie
Journal:  Can Urol Assoc J       Date:  2008-08       Impact factor: 1.862

3.  Voiding symptoms and urodynamic findings in patients with modified ileal neobladde.

Authors:  Attila Keszthelyi; Attila Majoros; Péter Nyirády; Peter Mayer; Dietmar Bach; Imre Romics
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

4.  Comparison of health-related quality of life (HRQoL) between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis.

Authors:  Hangchuan Shi; Han Yu; Joaquim Bellmunt; Jeffrey J Leow; Xuanyu Chen; Changcheng Guo; Hongmei Yang; Xiaoping Zhang
Journal:  Qual Life Res       Date:  2018-06-20       Impact factor: 4.147

5.  Quality of Life in Patients with Bladder Cancer Undergoing Ileal Conduit: A Comparison of Women Versus Men.

Authors:  Salvatore Siracusano; Carolina D'Elia; Maria Angela Cerruto; Omar Saleh; Sergio Serni; Mauro Gacci; Stefano Ciciliato; Alchiede Simonato; Antonio Porcaro; Vincenzo DE Marco; Renato Talamini; Laura Toffoli; Francesco Visalli; Mauro Niero; Cristina Lonardi; Ciro Imbimbo; Paolo Verze; Vincenzo Mirone; Marco Racioppi; Massimo Iafrate; Giovanni Cacciamani; Davide DE Marchi; Pierfrancesco Bassi; Walter Artibani
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

Review 6.  Is Health-Related Quality of Life after Radical Cystectomy Using Validated Questionnaires Really Better in Patients with Ileal Orthotopic Neobladder Compared to Ileal Conduit: A Meta-Analysis of Retrospective Comparative Studies.

Authors:  Maria A Cerruto; Carolina D'Elia; Salvatore Siracusano; Antonio B Porcaro; Giovanni Cacciamani; Davide De Marchi; Mauro Niero; Cristina Lonardi; Massimo Iafrate; Pierfrancesco Bassi; Emanuele Belgrano; Ciro Imbimbo; Marco Racioppi; Renato Talamini; Stefano Ciciliato; Laura Toffoli; Michele Rizzo; Francesco Visalli; Paolo Verze; Walter Artibani
Journal:  Curr Urol       Date:  2017-05-30

7.  [Patients' acceptance of urinary diversion. The pouch of Sisyphus].

Authors:  F-C von Rundstedt; S Roth; C R J Woodhouse; W Månsson; E W Gerharz
Journal:  Urologe A       Date:  2012-04       Impact factor: 0.639

8.  Quality of life and functional outcomes after radical cystectomy with ileal orthotopic neobladder replacement for bladder cancer: a multicentre observational study.

Authors:  E Pons-Tostivint; M Roumiguié; V Tostivint; G Verhoest; B Cabarrou; J Gas; P Coloby; J Zgheib; M Thoulouzan; M Soulié; X Gamé; J B Beauval
Journal:  World J Urol       Date:  2020-10-16       Impact factor: 4.226

Review 9.  Orthotopic neobladder reconstruction.

Authors:  Dwayne T S Chang; Nathan Lawrentschuk
Journal:  Urol Ann       Date:  2015 Jan-Mar

10.  Muscle invasive bladder cancer: from diagnosis to survivorship.

Authors:  N E Mohamed; M A Diefenbach; H H Goltz; C T Lee; D Latini; M Kowalkowski; C Philips; W Hassan; S J Hall
Journal:  Adv Urol       Date:  2012-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.